Reading this on a mobile device? Try our optimized mobile version here:

December 28, 2012
Sign upForwardArchiveAdvertise
News for nuclear medicine and molecular imaging professionals
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items below are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at

  Top Story 
  • India to establish isotope facility in Kolkata
    India is set to open a medical isotope facility in Kolkata in the middle of next year. The facility will focus on producing radioisotopes that emit gamma rays and positrons. The center, anticipated to be commissioned by 2014, will limit the country's dependence on imported isotopes and reduce costs, said Malay Kanti Das, head of the regional center of the Board of Radiation and Isotope Technology in Kolkata. Hindustan Times (India) (12/28) LinkedInFacebookTwitterEmail this Story
  Clinical News & Research 
  • Researchers explore earthworms as biological source of quantum dots
    Researchers are exploring the earthworm as a biological environment for creating CdTe quantum dots, substances that can function as medical imaging agents. The dots are capable of absorbing UV light and fluorescing in the green area of the spectrum. Tests involving cancer cells in a culture dish showed the cells were able to absorb the quantum dots and glow green following exposure to UV light, according to the study published in Nature Nanotechnology. The researchers said there is a need to develop a storage system that will allow the dots to be more effective for a longer period of time. Ars Technica (12/26) LinkedInFacebookTwitterEmail this Story
  Industry Report 
  • Actinium Pharmaceuticals raises $5.1M for drug development
    Actinium Pharmaceuticals, which specializes in alpha radioimmunotherapies for advanced cancers, has raised $5.1 million in a funding round. The company said it will use the money to advance its lead drug candidate for acute myeloid leukemia, Actimab-A, and its bone marrow conditioning agent Iomab-B, used in preparing patients for hematopoietic stem cell transplants. Newswire/News release (12/26) LinkedInFacebookTwitterEmail this Story
  News from the Field 
  • 5 key resolutions to help medtech sector prepare for years ahead
    The medtech industry is entering a new era in which medical devices must prove to be effective and reduce health care costs. This article offers five key resolutions to aid medtech firms in bracing for the new year and beyond, including boosting efforts targeted at foreign markets, making innovative products for the domestic market and enlisting the help of medical economists. (12/26) LinkedInFacebookTwitterEmail this Story
  International Developments 
  • Australian officials review ANSTO's nuclear med plans
    The Australian Parliament's Standing Committee on Public Works has started a routine consultation process into the Australian Nuclear Science and Technology Organisation's proposed nuclear medicine and Synroc waste treatment plants. The nuclear medicine manufacturing plant is expected to be finished by 2016 and will focus on producing molybdenum-99. The Synroc technology involves the storage of radioactive waste in synthetic rock, a method projected to cut the volume of nuclear byproducts by 99% compared with other storage procedures. St. George and Sutherland Shire Leader (Australia) (12/28) LinkedInFacebookTwitterEmail this Story
  Health Policy 
  Advancing Health Care 
  • NYU professor offers 6 ways to make science more reliable
    Rewarding the quality of research instead of the quantity of published papers, encouraging researchers to publish studies that failed and promoting meta-analysis would go a long way toward making science more reliable and reproducible, writes New York University professor Gary Marcus. He also suggests creating and enforcing a code of ethics and reminds researchers, the public and the media that a single study does not prove anything. The New Yorker (free content)/News Desk blog (12/24) LinkedInFacebookTwitterEmail this Story
  From SNMMI 
SNMMI  |  News  |  Meetings  |  Education  |  Publications  |  Membership

SNMMI on Facebook  |  SNMMI on LinkedIn  |  SNMMI on Twitter  |  SNMMI on YouTube

If all misfortunes were laid in one common heap whence everyone must take an equal portion, most people would be contented to take their own and depart."
Greek philosopher

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format  | Web version  | Search past news  | Archive  | Privacy policy

Account Director:   Meryl Harold   (202) 407-7828
 Recent SNMMI SmartBrief Issues:   Lead Editor:   Melissa Turner
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2013 SmartBrief, Inc.®  Legal Information